Gene Therapy for the Treatment of Primary Immune Deficiencies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-04-07

AUTHORS

Caroline Y. Kuo, Donald B. Kohn

ABSTRACT

The use of gene therapy in the treatment of primary immune deficiencies (PID) has advanced significantly in the last decade. Clinical trials for X-linked severe combined immunodeficiency, adenosine deaminase deficiency (ADA), chronic granulomatous disease, and Wiskott-Aldrich syndrome have demonstrated that gene transfer into hematopoietic stem cells and autologous transplant can result in clinical improvement and is curative for many patients. Unfortunately, early clinical trials were complicated by vector-related insertional mutagenic events for several diseases with the exception of ADA-deficiency SCID. These results prompted the current wave of clinical trials for primary immunodeficiency using alternative retro- or lenti-viral vector constructs that are self-inactivating, and they have shown clinical efficacy without leukemic events thus far. The field of gene therapy continues to progress, with improvements in viral vector profiles, stem cell culturing techniques, and site-specific genome editing platforms. The future of gene therapy is promising, and we are quickly moving towards a time when it will be a standard cellular therapy for many forms of PID. More... »

PAGES

39

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11882-016-0615-8

DOI

http://dx.doi.org/10.1007/s11882-016-0615-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047596369

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27056559


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/10", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Technology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1004", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biotechnology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Diseases, X-Linked", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunologic Deficiency Syndromes", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuo", 
        "givenName": "Caroline Y.", 
        "id": "sg:person.0702215134.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702215134.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Division of Hematology & Oncology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA", 
            "Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kohn", 
        "givenName": "Donald B.", 
        "id": "sg:person.01231045607.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231045607.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature05218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051754687", 
          "https://doi.org/10.1038/nature05218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10875-014-0101-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027201207", 
          "https://doi.org/10.1007/s10875-014-0101-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1095-1017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013283766", 
          "https://doi.org/10.1038/nm1095-1017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10875-015-0198-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013312337", 
          "https://doi.org/10.1007/s10875-015-0198-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-04-07", 
    "datePublishedReg": "2016-04-07", 
    "description": "The use of gene therapy in the treatment of primary immune deficiencies (PID) has advanced significantly in the last decade. Clinical trials for X-linked severe combined immunodeficiency, adenosine deaminase deficiency (ADA), chronic granulomatous disease, and Wiskott-Aldrich syndrome have demonstrated that gene transfer into hematopoietic stem cells and autologous transplant can result in clinical improvement and is curative for many patients. Unfortunately, early clinical trials were complicated by vector-related insertional mutagenic events for several diseases with the exception of ADA-deficiency SCID. These results prompted the current wave of clinical trials for primary immunodeficiency using alternative retro- or lenti-viral vector constructs that are self-inactivating, and they have shown clinical efficacy without leukemic events thus far. The field of gene therapy continues to progress, with improvements in viral vector profiles, stem cell culturing techniques, and site-specific genome editing platforms. The future of gene therapy is promising, and we are quickly moving towards a time when it will be a standard cellular therapy for many forms of PID.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11882-016-0615-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2416586", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1029244", 
        "issn": [
          "1529-7322", 
          "1534-6315"
        ], 
        "name": "Current Allergy and Asthma Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "gene therapy", 
      "adenosine deaminase deficiency", 
      "genome editing platform", 
      "primary immune deficiency", 
      "deaminase deficiency", 
      "vector constructs", 
      "leukemic events", 
      "cell culturing techniques", 
      "clinical trials", 
      "gene transfer", 
      "editing platform", 
      "Wiskott-Aldrich syndrome", 
      "immune deficiency", 
      "stem cells", 
      "hematopoietic stem cells", 
      "early clinical trials", 
      "chronic granulomatous disease", 
      "cellular therapy", 
      "clinical improvement", 
      "autologous transplant", 
      "clinical efficacy", 
      "granulomatous disease", 
      "primary immunodeficiency", 
      "therapy", 
      "mutagenic events", 
      "trials", 
      "platform", 
      "immunodeficiency", 
      "disease", 
      "deficiency", 
      "treatment", 
      "improvement", 
      "vector profiles", 
      "patients", 
      "transplant", 
      "syndrome", 
      "SCID", 
      "culturing techniques", 
      "last decade", 
      "efficacy", 
      "technique", 
      "events", 
      "cells", 
      "future", 
      "waves", 
      "transfer", 
      "results", 
      "field", 
      "use", 
      "profile", 
      "exception", 
      "current wave", 
      "time", 
      "decades", 
      "constructs", 
      "form", 
      "vector-related insertional mutagenic events", 
      "insertional mutagenic events", 
      "ADA-deficiency SCID", 
      "lenti-viral vector constructs", 
      "viral vector profiles", 
      "site-specific genome editing platforms", 
      "standard cellular therapy", 
      "forms of PID"
    ], 
    "name": "Gene Therapy for the Treatment of Primary Immune Deficiencies", 
    "pagination": "39", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047596369"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11882-016-0615-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27056559"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11882-016-0615-8", 
      "https://app.dimensions.ai/details/publication/pub.1047596369"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_702.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11882-016-0615-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11882-016-0615-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11882-016-0615-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11882-016-0615-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11882-016-0615-8'


 

This table displays all metadata directly associated to this object as RDF triples.

190 TRIPLES      22 PREDICATES      103 URIs      91 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11882-016-0615-8 schema:about N0100eb89523147d9b52dac2e7452d783
2 N511121ff1b8b42888d7ae0ccecab4747
3 N8d61809a4c534c319754aed396f13161
4 N8fcef5d8d8644238a1f13a81343aa326
5 Nb4fe238cf4cd4721b0725a7a78540327
6 Nb659cb303761469081b6300abdcba773
7 Nb85d1e85e1ab4dc480735cdbfc13c644
8 Nc91f0c0ca5444786ab627c4f27c122c7
9 Nf4d5c24b4e824ec88f453a1bc3a509e4
10 anzsrc-for:10
11 anzsrc-for:1004
12 schema:author N8099032349634e299e32aa9600df070d
13 schema:citation sg:pub.10.1007/s10875-014-0101-9
14 sg:pub.10.1007/s10875-015-0198-5
15 sg:pub.10.1038/nature05218
16 sg:pub.10.1038/nm1095-1017
17 schema:datePublished 2016-04-07
18 schema:datePublishedReg 2016-04-07
19 schema:description The use of gene therapy in the treatment of primary immune deficiencies (PID) has advanced significantly in the last decade. Clinical trials for X-linked severe combined immunodeficiency, adenosine deaminase deficiency (ADA), chronic granulomatous disease, and Wiskott-Aldrich syndrome have demonstrated that gene transfer into hematopoietic stem cells and autologous transplant can result in clinical improvement and is curative for many patients. Unfortunately, early clinical trials were complicated by vector-related insertional mutagenic events for several diseases with the exception of ADA-deficiency SCID. These results prompted the current wave of clinical trials for primary immunodeficiency using alternative retro- or lenti-viral vector constructs that are self-inactivating, and they have shown clinical efficacy without leukemic events thus far. The field of gene therapy continues to progress, with improvements in viral vector profiles, stem cell culturing techniques, and site-specific genome editing platforms. The future of gene therapy is promising, and we are quickly moving towards a time when it will be a standard cellular therapy for many forms of PID.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree true
23 schema:isPartOf N1ca00ec79d86492ca2fe4d0d81cb14aa
24 Nc71de4a8c6f7491dba14843aef197070
25 sg:journal.1029244
26 schema:keywords ADA-deficiency SCID
27 SCID
28 Wiskott-Aldrich syndrome
29 adenosine deaminase deficiency
30 autologous transplant
31 cell culturing techniques
32 cells
33 cellular therapy
34 chronic granulomatous disease
35 clinical efficacy
36 clinical improvement
37 clinical trials
38 constructs
39 culturing techniques
40 current wave
41 deaminase deficiency
42 decades
43 deficiency
44 disease
45 early clinical trials
46 editing platform
47 efficacy
48 events
49 exception
50 field
51 form
52 forms of PID
53 future
54 gene therapy
55 gene transfer
56 genome editing platform
57 granulomatous disease
58 hematopoietic stem cells
59 immune deficiency
60 immunodeficiency
61 improvement
62 insertional mutagenic events
63 last decade
64 lenti-viral vector constructs
65 leukemic events
66 mutagenic events
67 patients
68 platform
69 primary immune deficiency
70 primary immunodeficiency
71 profile
72 results
73 site-specific genome editing platforms
74 standard cellular therapy
75 stem cells
76 syndrome
77 technique
78 therapy
79 time
80 transfer
81 transplant
82 treatment
83 trials
84 use
85 vector constructs
86 vector profiles
87 vector-related insertional mutagenic events
88 viral vector profiles
89 waves
90 schema:name Gene Therapy for the Treatment of Primary Immune Deficiencies
91 schema:pagination 39
92 schema:productId N460c56949aff4297afd64581e765669e
93 N6e850452b1664540b219efcfe8a5e1b4
94 N7d2c9f5ad92c4114b8e998ed47fe130e
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047596369
96 https://doi.org/10.1007/s11882-016-0615-8
97 schema:sdDatePublished 2021-12-01T19:37
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher Ncddc5df1a588430889425503e28bd5a0
100 schema:url https://doi.org/10.1007/s11882-016-0615-8
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N0100eb89523147d9b52dac2e7452d783 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Bone Marrow Cells
106 rdf:type schema:DefinedTerm
107 N1ca00ec79d86492ca2fe4d0d81cb14aa schema:issueNumber 5
108 rdf:type schema:PublicationIssue
109 N22eba18c715d40bf8fa94b0ae06c91b2 rdf:first sg:person.01231045607.82
110 rdf:rest rdf:nil
111 N460c56949aff4297afd64581e765669e schema:name pubmed_id
112 schema:value 27056559
113 rdf:type schema:PropertyValue
114 N511121ff1b8b42888d7ae0ccecab4747 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Genetic Diseases, X-Linked
116 rdf:type schema:DefinedTerm
117 N6e850452b1664540b219efcfe8a5e1b4 schema:name doi
118 schema:value 10.1007/s11882-016-0615-8
119 rdf:type schema:PropertyValue
120 N7d2c9f5ad92c4114b8e998ed47fe130e schema:name dimensions_id
121 schema:value pub.1047596369
122 rdf:type schema:PropertyValue
123 N8099032349634e299e32aa9600df070d rdf:first sg:person.0702215134.54
124 rdf:rest N22eba18c715d40bf8fa94b0ae06c91b2
125 N8d61809a4c534c319754aed396f13161 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Genetic Therapy
127 rdf:type schema:DefinedTerm
128 N8fcef5d8d8644238a1f13a81343aa326 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Animals
130 rdf:type schema:DefinedTerm
131 Nb4fe238cf4cd4721b0725a7a78540327 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Immunologic Deficiency Syndromes
133 rdf:type schema:DefinedTerm
134 Nb659cb303761469081b6300abdcba773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 Nb85d1e85e1ab4dc480735cdbfc13c644 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Hematopoietic Stem Cells
139 rdf:type schema:DefinedTerm
140 Nc71de4a8c6f7491dba14843aef197070 schema:volumeNumber 16
141 rdf:type schema:PublicationVolume
142 Nc91f0c0ca5444786ab627c4f27c122c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Hematopoietic Stem Cell Transplantation
144 rdf:type schema:DefinedTerm
145 Ncddc5df1a588430889425503e28bd5a0 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nf4d5c24b4e824ec88f453a1bc3a509e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Bone Marrow Transplantation
149 rdf:type schema:DefinedTerm
150 anzsrc-for:10 schema:inDefinedTermSet anzsrc-for:
151 schema:name Technology
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1004 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical Biotechnology
155 rdf:type schema:DefinedTerm
156 sg:grant.2416586 http://pending.schema.org/fundedItem sg:pub.10.1007/s11882-016-0615-8
157 rdf:type schema:MonetaryGrant
158 sg:journal.1029244 schema:issn 1529-7322
159 1534-6315
160 schema:name Current Allergy and Asthma Reports
161 schema:publisher Springer Nature
162 rdf:type schema:Periodical
163 sg:person.01231045607.82 schema:affiliation grid-institutes:grid.19006.3e
164 schema:familyName Kohn
165 schema:givenName Donald B.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231045607.82
167 rdf:type schema:Person
168 sg:person.0702215134.54 schema:affiliation grid-institutes:grid.19006.3e
169 schema:familyName Kuo
170 schema:givenName Caroline Y.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702215134.54
172 rdf:type schema:Person
173 sg:pub.10.1007/s10875-014-0101-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027201207
174 https://doi.org/10.1007/s10875-014-0101-9
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s10875-015-0198-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013312337
177 https://doi.org/10.1007/s10875-015-0198-5
178 rdf:type schema:CreativeWork
179 sg:pub.10.1038/nature05218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051754687
180 https://doi.org/10.1038/nature05218
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/nm1095-1017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013283766
183 https://doi.org/10.1038/nm1095-1017
184 rdf:type schema:CreativeWork
185 grid-institutes:grid.19006.3e schema:alternateName Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA
186 Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
187 schema:name Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA
188 Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
189 Division of Hematology & Oncology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
190 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...